Literature DB >> 21856154

New betulinic acid derivatives as potent proteasome inhibitors.

Keduo Qian1, Sang-Yong Kim, Hsin-Yi Hung, Li Huang, Chin-Ho Chen, Kuo-Hsiung Lee.   

Abstract

In this study, 22 new betulinic acid (BA) derivatives were synthesized and tested for their inhibition of the chymotrypsin-like activity of 20S proteasome. From the SAR study, we concluded that the C-3 and C-30 positions are the pharmacophores for increasing the proteasome inhibition effects, and larger lipophilic or aromatic side chains are favored at these positions. Among the BA derivatives tested, compounds 13, 20, and 21 showed the best proteasome inhibition activity with IC(50) values of 1.42, 1.56, and 1.80 μM, respectively, which are three to fourfold more potent than the proteasome inhibition controls LLM-F and lactacystin.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856154      PMCID: PMC3171619          DOI: 10.1016/j.bmcl.2011.07.072

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

1.  Betulinic acid: isolation from Triphyophyllum peltatum and Ancistrocladus heyneanus, antimalarial activity, and crystal structure of the benzyl ester.

Authors:  G Bringmann; W Saeb; L A Assi; G François; A S Sankara Narayanan; K Peters; E M Peters
Journal:  Planta Med       Date:  1997-06       Impact factor: 3.352

2.  Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid.

Authors:  I-Chen Sun; Chin-Ho Chen; Yoshiki Kashiwada; Jiu-Hong Wu; Hui-Kang Wang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2002-09-12       Impact factor: 7.446

3.  Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.

Authors:  Li Huang; Donglei Yu; Phong Ho; Keduo Qian; Kuo-Hsiung Lee; Chin-Ho Chen
Journal:  Bioorg Med Chem       Date:  2008-06-05       Impact factor: 3.641

4.  Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.

Authors:  Y Kashiwada; F Hashimoto; L M Cosentino; C H Chen; P E Garrett; K H Lee
Journal:  J Med Chem       Date:  1996-03-01       Impact factor: 7.446

5.  Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.

Authors:  T Kanamoto; Y Kashiwada; K Kanbara; K Gotoh; M Yoshimori; T Goto; K Sano; H Nakashima
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  Terpenoids of Syzygium formosanum.

Authors:  C W Chang; T S Wu; Y S Hsieh; S C Kuo; P D Chao
Journal:  J Nat Prod       Date:  1999-02       Impact factor: 4.050

Review 7.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

8.  PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Authors:  F Li; R Goila-Gaur; K Salzwedel; N R Kilgore; M Reddick; C Matallana; A Castillo; D Zoumplis; D E Martin; J M Orenstein; G P Allaway; E O Freed; C T Wild
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-22       Impact factor: 11.205

9.  Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.

Authors:  Li Huang; Xiong Yuan; Christopher Aiken; Chin Ho Chen
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Activation and inhibition of the proteasome by betulinic acid and its derivatives.

Authors:  Li Huang; Phong Ho; Chin-Ho Chen
Journal:  FEBS Lett       Date:  2007-09-24       Impact factor: 4.124

View more
  6 in total

1.  Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats.

Authors:  Bryan Killinger; Mrudang Shah; Anna Moszczynska
Journal:  J Neurochem       Date:  2013-12-03       Impact factor: 5.372

2.  Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.

Authors:  Puranik Purushottamachar; Abhijit M Godbole; Lalji K Gediya; Marlena S Martin; Tadas S Vasaitis; Andrew K Kwegyir-Afful; Senthilmurugan Ramalingam; Zeynep Ates-Alagoz; Vincent C O Njar
Journal:  J Med Chem       Date:  2013-06-07       Impact factor: 7.446

3.  A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy.

Authors:  Tsung-I Hsu; Ying-Jung Chen; Chia-Yang Hung; Yi-Chang Wang; Sin-Jin Lin; Wu-Chou Su; Ming-Derg Lai; Sang-Yong Kim; Qiang Wang; Keduo Qian; Masuo Goto; Yu Zhao; Yoshiki Kashiwada; Kuo-Hsiung Lee; Wen-Chang Chang; Jan-Jong Hung
Journal:  Oncotarget       Date:  2015-05-30

4.  Cytotoxic conjugates of betulinic acid and substituted triazoles prepared by Huisgen Cycloaddition from 30-azidoderivatives.

Authors:  Veronika Sidova; Pavel Zoufaly; Jan Pokorny; Petr Dzubak; Marian Hajduch; Igor Popa; Milan Urban
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

5.  Two series of new semisynthetic triterpene derivatives: differences in anti-malarial activity, cytotoxicity and mechanism of action.

Authors:  Gloria N S da Silva; Nicole R G Maria; Desirée C Schuck; Laura N Cruz; Miriam S de Moraes; Myna Nakabashi; Cedric Graebin; Grace Gosmann; Célia R S Garcia; Simone C B Gnoatto
Journal:  Malar J       Date:  2013-03-09       Impact factor: 2.979

6.  Antineoplastic agents. 595. Structural modifications of betulin and the X-ray crystal structure of an unusual betulin amine dimer.

Authors:  George R Pettit; Noeleen Melody; Frank Hempenstall; Jean-Charles Chapuis; Thomas L Groy; Lee Williams
Journal:  J Nat Prod       Date:  2014-04-02       Impact factor: 4.050

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.